Last reviewed · How we verify
Sitagliptin combined with Beidougen capsule — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Sitagliptin combined with Beidougen capsule (Sitagliptin combined with Beidougen capsule) — Beijing Chao Yang Hospital.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Sitagliptin combined with Beidougen capsule TARGET | Sitagliptin combined with Beidougen capsule | Beijing Chao Yang Hospital | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Sitagliptin combined with Beidougen capsule CI watch — RSS
- Sitagliptin combined with Beidougen capsule CI watch — Atom
- Sitagliptin combined with Beidougen capsule CI watch — JSON
- Sitagliptin combined with Beidougen capsule alone — RSS
Cite this brief
Drug Landscape (2026). Sitagliptin combined with Beidougen capsule — Competitive Intelligence Brief. https://druglandscape.com/ci/sitagliptin-combined-with-beidougen-capsule. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab